person · Reporting owner
Meluzio Michael Vincent
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | VP, Prin. Accounting Officer | October 12, 2026 | October 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date October 12, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,817 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 1,144 · Balance 47,817 F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 15, 2026 01:38 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 1,144 | $28.05 | $32,089.20 |
DisclosureSEC source: 0002138368-26-000009 · form4-10152026_011010.xml · nonDerivative · entry 1 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,817 F1 · kind: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:19 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock · Derivative | 13,647 | $0.00 | $0.00 |
DisclosureSEC source: 0002138368-26-000007 · form4-08172026_100852.xml · derivative · entry 5 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,295 Underlying: Common Stock · 13,647 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. F4 · derivative.exercise_date: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. F4 · derivative.expiration_date: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:19 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 3 | $31.13 | $93.39 |
DisclosureSEC source: 0002138368-26-000007 · form4-08172026_100852.xml · nonDerivative · entry 4 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,961 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:19 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 4,106 | $30.35 | $124,617.10 |
DisclosureSEC source: 0002138368-26-000007 · form4-08172026_100852.xml · nonDerivative · entry 3 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,964 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F3 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $29.99 to $30.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:19 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 1,519 | $29.37 | $44,613.03 |
DisclosureSEC source: 0002138368-26-000007 · form4-08172026_100852.xml · nonDerivative · entry 2 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,070 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F2 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.97 to $29.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:19 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 13,647 | $0.00 | $0.00 |
DisclosureSEC source: 0002138368-26-000007 · form4-08172026_100852.xml · nonDerivative · entry 1 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:34 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock · Derivative | 40,942 | $0.00 | $0.00 |
DisclosureSEC source: 0002138368-26-000005 · form4-07102026_110720.xml · derivative · entry 2 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,942 Underlying: Common Stock · 40,942 shares Expires not disclosed F2 · derivative.exercise_price: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. F2 · derivative.exercise_date: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. F2 · derivative.expiration_date: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:34 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 40,942 | $0.00 | $0.00 |
DisclosureSEC source: 0002138368-26-000005 · form4-07102026_110720.xml · nonDerivative · entry 1 Meluzio Michael Vincent · CIK 0002138368 · VP, Prin. Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,942 F1 · shares: Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.